A5044648290- Liver Disease Diagnosis and Treatment
- Lipoproteins and Cardiovascular Health
- Cholesterol and Lipid Metabolism
- Cancer, Lipids, and Metabolism
- Diabetes Treatment and Management
- Diet, Metabolism, and Disease
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Kruppel-like factors research
- Endoplasmic Reticulum Stress and Disease
- Fibroblast Growth Factor Research
- Heart Failure Treatment and Management
- Lipid metabolism and disorders
- Calpain Protease Function and Regulation
- Hepatitis C virus research
- Pancreatitis Pathology and Treatment
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Atherosclerosis and Cardiovascular Diseases
- Drug Transport and Resistance Mechanisms
- Heat shock proteins research
- Birth, Development, and Health
- Peroxisome Proliferator-Activated Receptors
- Diet and metabolism studies
- Pharmaceutical Practices and Patient Outcomes
- Medication Adherence and Compliance
Netherlands Organisation for Applied Scientific Research
2022-2025
Leiden University
2025
Leiden University Medical Center
2022-2024
Netherlands Metabolomics Centre
2023
Utrecht University
2020-2021
University Medical Center Utrecht
2021
Semaglutide, a glucagon-like peptide-1 receptor agonist, is an antidiabetic medication that has recently been approved for the treatment of obesity as well. Semaglutide postulated to be promising candidate non-alcoholic steatohepatitis (NASH). Here, Ldlr-/-.Leiden mice received fast-food diet (FFD) 25 weeks, followed by another 12 weeks on FFD with daily subcutaneous injections semaglutide or vehicle (control). Plasma parameters were evaluated, livers and hearts examined, hepatic...
Atherosclerosis is the major cause of cardiovascular disease. This study evaluated effect lipid lowering using a novel peptide inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) and monoclonal antibody against angiopoietin-like 3 (evinacumab), either alone or in combination APOE*3-Leiden.CETP mice fed Western diet. Effects on body weight, plasma lipids, atherosclerotic lesion size, severity, composition morphology were assessed. Treatment with PCSK9 inhibitory significantly...
Patients with metabolic syndrome are often prescribed statins to prevent the development of cardiovascular disease. Conversely, data on their effects non-alcoholic steatohepatitis (NASH) lacking. We evaluated these by feeding APOE*3-Leiden mice a Western-type diet (WTD) or without atorvastatin induce NASH and hepatic fibrosis. Besides well-known plasma cholesterol lowering (-30%) anti-atherogenic (severe lesion size -48%), significantly reduced steatosis (-22%), number aggregated...
Abstract Fibroblast growth factor 21 (FGF21) is a promising target for treatment of obesity‐associated diseases including metabolic dysfunction‐associated steatohepatitis (MASH) and atherosclerosis. We evaluated the effects bispecific anti‐FGF21‐β klotho (KLB) agonist antibody bFKB1 in preclinical model MASH Low‐density lipoprotein receptor knockout (Ldlr−/−).Leiden mice received high‐fat diet 20 weeks, followed by with an isotype control or 12 weeks. Effects on plasma risk markers...
Abstract Lifestyle interventions remain the treatment of choice for patients with obesity and metabolic complications, yet are difficult to maintain often lead cycles weight loss regain (weight cycling). Literature on cycling remains controversial we therefore investigated association between complications using preexistent obese mice. Ldlr−/−.Leiden mice received a high‐fat diet (HFD) 20 weeks induce obesity. Subsequently, weight‐cycled were switched healthy chow HFD four 2‐week periods...